Biomea Fusion's Ongoing Phase 2 Study of BMF-219 Shows Glycated Hemoglobin Reductions in Patients With Type 2 Diabetes
Biomea Fusion's Ongoing Phase 2 Study of BMF-219 Shows Glycated Hemoglobin Reductions in Patients With Type 2 Diabetes
Biomea Fusion 正在进行的 BMF-219 第 2 期研究显示 2 型糖尿病患者的糖化血红蛋白降低
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册